Literature DB >> 17923547

Optic neuritis associated with chikungunya virus infection in South India.

Apoorva Mittal1, Saurabh Mittal, M Jayahar Bharati, Rengappa Ramakrishnan, Sankarlingam Saravanan, Padmakar S Sathe.   

Abstract

OBJECTIVE: To define optic neuritis associated with chikungunya virus (CHIKV) infection in a clinical setting.
METHODS: This observational case series includes 14 patients with clinical features of CHIKV infection and associated optic neuritis. Complete ophthalmic evaluations were performed, as well as other examinations, including Mantoux test, Widal test, blood profile, color vision, neuroimaging, visual fields, visual evoked potentials, VDRL test, and enzyme-linked immunosorbent assay for CHIKV-specific immunoglobulin. Relevant clinical findings of optic neuritis associated with seropositive CHIKV infection were recorded.
RESULTS: Nineteen eyes (in 14 patients) had optic nerve involvement. The mean +/- SD patient age was 45.8 +/- 15.6 years. Eight eyes (42%) had papillitis, 4 eyes (21%) had retrobulbar neuritis, 4 eyes (21%) had retrochiasmal (optic tract) neuritis, and 3 eyes (16%) had neuroretinitis. Parenteral corticosteroids were administered in all patients. Color vision, visual fields, and best-corrected visual acuity of 6/12 (or 20/40 Snellen visual acuity) or better improved statistically significantly by the end of 3 weeks (P < .001). Partial to complete recovery of visual function was seen in 10 patients (71%). Four patients had a poor visual outcome; 3 of them were initially seen 1 month after onset of ocular symptoms.
CONCLUSIONS: Acute-onset visual loss due to optic neuritis may be associated with CHIKV infection. Visual recovery is good. Corticosteroids accelerated recovery when initiated at an early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923547     DOI: 10.1001/archopht.125.10.1381

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  31 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

Review 2.  Novel infectious agents causing uveitis.

Authors:  Moncef Khairallah; Soon Phaik Chee; Sivakumar R Rathinam; Sonia Attia; Venu Nadella
Journal:  Int Ophthalmol       Date:  2009-08-27       Impact factor: 2.031

Review 3.  Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.

Authors:  Victor J Drew; Lassina Barro; Jerard Seghatchian; Thierry Burnouf
Journal:  Blood Transfus       Date:  2017-04-13       Impact factor: 3.443

Review 4.  Viral posterior uveitis.

Authors:  Joanne H Lee; Aniruddha Agarwal; Padmamalini Mahendradas; Cecilia S Lee; Vishali Gupta; Carlos E Pavesio; Rupesh Agrawal
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 5.  Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology.

Authors:  Teck-Hui Teo; Fok-Moon Lum; Wendy W L Lee; Lisa F P Ng
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 6.  The Range of Neurological Complications in Chikungunya Fever.

Authors:  T Cerny; M Schwarz; U Schwarz; J Lemant; P Gérardin; E Keller
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

7.  Emergent infectious uveitis.

Authors:  Moncef Khairallah; Bechir Jelliti; Salah Jenzeri
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

Review 8.  Chikungunya: a potentially emerging epidemic?

Authors:  Michelle M Thiboutot; Senthil Kannan; Omkar U Kawalekar; Devon J Shedlock; Amir S Khan; Gopalsamy Sarangan; Padma Srikanth; David B Weiner; Karuppiah Muthumani
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

9.  Chikungunya fever presenting with acute optic neuropathy.

Authors:  Abhijit Anand Mohite; Adriana Agius-Fernandez
Journal:  BMJ Case Rep       Date:  2015-07-28

Review 10.  Chikungunya: an overview.

Authors:  A B Sudeep; D Parashar
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.